tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsTools for Trading PlatformsData for Hedge FundsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

AMGN Stock Latest News

Amgen (NASDAQ:AMGN) to Slash More Jobs in Second Round of Layoffs
Market NewsAmgen (NASDAQ:AMGN) to Slash More Jobs in Second Round of Layoffs
3d ago
AMGN
Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
The FlyStreet Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
7d ago
AAP
CBT
Wells Fargo upgrades Amgen to Overweight, lowers target to $265
The FlyWells Fargo upgrades Amgen to Overweight, lowers target to $265
7d ago
AMGN
HZNP
Amgen upgraded to Overweight from Equal Weight at Wells Fargo
The FlyAmgen upgraded to Overweight from Equal Weight at Wells Fargo
7d ago
AMGN
Cantor biopharma/biotech analysts to hold analyst/industry conference call
The FlyCantor biopharma/biotech analysts to hold analyst/industry conference call
11d ago
BMY
AMGN
Cantor biopharma/biotech analysts to hold analyst/industry conference call
The FlyCantor biopharma/biotech analysts to hold analyst/industry conference call
11d ago
BMY
AMGN
AMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND
Press ReleasesAMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND
13d ago
AMGN
Cantor biopharma/biotech analysts to hold analyst/industry conference call
The FlyCantor biopharma/biotech analysts to hold analyst/industry conference call
14d ago
BMY
AMGN
Amgen to present new Repatha combined data from  Phase 3 FOURIER trials
The FlyAmgen to present new Repatha combined data from Phase 3 FOURIER trials
19d ago
AMGN
Horizon Therapeutics reports Q4  EPS $1.21, consensus  $1.09
The FlyHorizon Therapeutics reports Q4 EPS $1.21, consensus $1.09
19d ago
AMGN
HZNP
Early notable gainers among liquid option names on February 17th
The FlyEarly notable gainers among liquid option names on February 17th
1M ago
DE
ABC
Amgen price target lowered to $260 from $280 at Truist
The FlyAmgen price target lowered to $260 from $280 at Truist
1M ago
AMGN
Amgen price target lowered to $270 from $300 at Argus
The FlyAmgen price target lowered to $270 from $300 at Argus
1M ago
AMGN
Amgen’s Tezspire approved in U.S. for self-administration in severe asthma
The FlyAmgen’s Tezspire approved in U.S. for self-administration in severe asthma
2M ago
AZN
AMGN
Amgen price target lowered to $267 from $282 at SVB Securities
The FlyAmgen price target lowered to $267 from $282 at SVB Securities
2M ago
AMGN
Amgen price target lowered to $275 from $285 at Wells Fargo
The FlyAmgen price target lowered to $275 from $285 at Wells Fargo
2M ago
AMGN
HZNP
Amgen price target lowered to $258 from $268 at RBC Capital
The FlyAmgen price target lowered to $258 from $268 at RBC Capital
2M ago
AMGN
HZNP
Amgen price target lowered to $253 from $276 at BMO Capital
The FlyAmgen price target lowered to $253 from $276 at BMO Capital
2M ago
AMGN
HZNP
Amgen price target lowered to $289 from $307 at Cowen
The FlyAmgen price target lowered to $289 from $307 at Cowen
2M ago
AMGN
Amgen price target lowered to $220 from $240 at Credit Suisse
The FlyAmgen price target lowered to $220 from $240 at Credit Suisse
2M ago
AMGN
Amgen price target lowered to $230 from $240 at Barclays
The FlyAmgen price target lowered to $230 from $240 at Barclays
2M ago
AMGN
Amgen, Horizon Therapeutics receive second request for additional info from FTC
The FlyAmgen, Horizon Therapeutics receive second request for additional info from FTC
2M ago
AMGN
HZNP
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
Press ReleasesAMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
2M ago
AMGN
Amgen sees FY23 CapEx about $925M
The FlyAmgen sees FY23 CapEx about $925M
2M ago
AMGN
Amgen sees FY23 adjusted EPS $17.40-$18.60, consensus $18.33
The FlyAmgen sees FY23 adjusted EPS $17.40-$18.60, consensus $18.33
2M ago
AMGN
Amgen reports Q4 adjusted EPS $4.09, consensus $4.09
The FlyAmgen reports Q4 adjusted EPS $4.09, consensus $4.09
2M ago
AMGN
Amgen options imply 3.2% move in share price post-earnings
The FlyAmgen options imply 3.2% move in share price post-earnings
2M ago
AMGN
Notable companies reporting after market close
The FlyNotable companies reporting after market close
2M ago
AMD
AMGN
AbbVie’s Humira drug faces competition in the U.S., FT reports
The FlyAbbVie’s Humira drug faces competition in the U.S., FT reports
2M ago
ABBV
AMGN
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.